ANVS — Annovis Bio, Inc.

—
NYSE · Health Care · Pharmaceuticals · CIK 1477845 ·
Last close
$0.74
Market Cap
$31.97M
52W High
$5.50
52W Low
$0.62
ADV30
2,560,739
Next earnings
—
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer's disease, as well as in open-label phase 3 to treat parkinson's disease. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia. Annovis Bio, Inc. was incorporated in 2008 and is headquartered in Malvern, Pennsylvania.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 — — — — — — —
Jun 2026 0 — -14,377,712 -14,820,815 22,037,091 18,728,945 26,291,709
Mar 2026 0 — -18,012,182 -17,606,382 16,243,703 14,219,081 13,117,645
Dec 2025 0 — -9,706,149 -9,834,412 21,081,625 19,532,338 4,230,375

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-43,339,894
Investing CF
—
Financing CF
$44,938,553
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.72
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-196,130,856
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-49,531,018
Pretax Income TTM
$-49,524,267
Interest Exp TTM
—
Analysts
4

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -29,695,258 -28,854,197 21,081,625 4,230,375 16,851,250 -25,619,703
Dec 2024 0 -26,694,928 -24,590,375 13,925,633 4,617,987 9,307,646 -21,894,604
Dec 2023 0 -45,035,011 -56,204,313 10,208,264 17,959,110 -7,750,846 -39,967,304
Dec 2022 0 -25,511,279 -25,328,567 36,022,069 7,698,539 28,323,530 -17,312,934

TTM Snapshot

Revenues TTM
$618,087
NetIncome TTM
$-49,524,267
OpCashFlow TTM
—
Assets (Latest)
$22,037,091
Forward EPS
$-0.86

Max Pain — expiry 2026-11-27 (volume-derived — Yahoo OI feed degraded)

max pain strike: $0.50 · spot: $0.84 · call volume: 670 · put volume: 0

Peers — same industry

TickerNameMarket CapLastDaily %
TELO Telomir Pharmaceuticals, Inc. $31.17M $0.42 —
RNTX Rein Therapeutics, Inc. $30.75M $0.36 —
NXTC NextCure, Inc. $30.68M $6.70 —
BCTX BriaCell Therapeutics Corp. $30.65M $3.51 —
NSRX Nasus Pharma Ltd $30.57M $2.61 —

News headlines (Yahoo Finance, 1h cache)

Annovis Receives Second Positive DSMB Recommendation for its Phase 3 DUET-AD Study
2026-11-17 13:00 · Yahoo
Annovis Provides Corporate Updates and Reports Third Quarter 2026 Financial Results
2026-11-13 13:00 · Yahoo
Annovis Bio Granted U.S. Patent Covering New Crystalline Form of Buntanetap
2026-11-12 13:00 · Yahoo
Annovis Announces Closing of $21.0 Million Public Offering with 24% Contribution from the Board Chairman
2026-11-09 12:00 · Yahoo
Annovis Announces Pricing of $21.0 Million Public Offering
2026-11-05 13:05 · Yahoo
Annovis Announces Launch of Proposed Public Offering
2026-11-04 21:07 · Yahoo
Annovis Bio, Inc. Receives Continued Listing Standard Notice from the NYSE
2026-10-30 21:00 · Yahoo
Annovis to Participate in U.S. Biotech Day 2026 and Pharma Partnering Summit 2026
2026-10-29 12:00 · Yahoo
Annovis to Attend the CTAD 2026 with Three Presentations
2026-10-22 12:00 · Yahoo
Annovis Bio (ANVS) Loses 26.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
2026-09-08 13:35 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.